pierce this barrier to successful immunotherapy. Finally, success in the case of infectious disease has a prophylactic setting, whereas the challenge of cancer lies in the domain of treating pre ...

“Because we have the potential to turn non-immunogenic components into strong immunogens, we are in a position to leverage the full potential of immunotherapy, including prophylactic applications.

Many of the different antigens used in immunotherapy have very low affinities for their MHC molecules. Therefore, immunotherapies have been enhanced by the modification of the antigenic peptide by ...

After decades of disappointment, active immunotherapy with vaccines, as well as passive immunotherapy using unmodified and armed monoclonal antibodies, are emerging as useful immunotherapeutic ...

Prophylactic measures are crucial to reduce infection-related morbidity and mortality in MM patients, especially before immunotherapy becomes widespread. The study provides a baseline for ...

“We aim to develop BioNTech into a global immunotherapy powerhouse with the potential to improve the standard of care with innovative oncology products and prophylactic vaccines against ...